Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Dermatomyositis
ADR ID BADD_A01225
ADR Hierarchy
15      Musculoskeletal and connective tissue disorders
15.05      Muscle disorders
15.05.01      Muscle infections and inflammations
15.05.01.002      Dermatomyositis
23      Skin and subcutaneous tissue disorders
23.03      Epidermal and dermal conditions
23.03.02      Connective tissue disorders
23.03.02.001      Dermatomyositis
10      Immune system disorders
10.04      Autoimmune disorders
10.04.04      Autoimmune disorders NEC
10.04.04.027      Dermatomyositis
Description A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) [MeSH]
MedDRA Code 10012503
MeSH ID D003882
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Adult dermatomyositis | Childhood dermatomyositis | Dermatomyositis | Gottron's papules | Juvenile dermatomyositis | Polymyositis-Dermatomyositis | Polymyositis Dermatomyositis | Dermatomyositis, Adult Type | Adult Type Dermatomyositis | Dermatomyositis, Childhood Type | Childhood Type Dermatomyositis | Juvenile Dermatomyositis | Dermatomyositis, Juvenile | Dermatopolymyositis | Juvenile Myositis | Myositis, Juvenile
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00066Alendronic acid0.000044%
BADD_D00142Anastrozole0.000397%
BADD_D00165Aripiprazole0.000079%
BADD_D00195Azathioprine0.000313%
BADD_D00349Capecitabine0.000638%
BADD_D00415Cerivastatin--
BADD_D00480Clarithromycin0.000558%
BADD_D00504Clopidogrel0.000021%
BADD_D00549Cyclophosphamide--
BADD_D00551Cyclosporine0.000221%
BADD_D00786Eplerenone0.007424%
BADD_D00864Ezetimibe--
BADD_D00979Furosemide0.000028%
BADD_D01110Hydroxyurea0.000448%
BADD_D01149Indapamide0.000754%
BADD_D01171Interferon gamma-1b--
BADD_D01213Isotretinoin--
BADD_D01257Letrozole0.000659%
BADD_D01325Lovastatin--
BADD_D01418Methotrexate0.000114%
BADD_D01470Minocycline--
BADD_D01567Nilotinib0.000112%
BADD_D01601Olaparib0.000873%
BADD_D01653Paclitaxel0.000280%
BADD_D01709Penicillamine--
BADD_D01822Prasugrel0.000384%
BADD_D01824Pravastatin--
BADD_D01825Pravastatin sodium--
BADD_D01831Prednisolone0.000105%
BADD_D01834Prednisone0.000027%
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
ADR Term Drug Name Target